Compound ID | 672

Update compound information

NVD PDF713

Synonym(s): LBM415  |  LBM-415  |  LBM 415  |  NVD PDF 713  |  NVD PDF-713  |  VIC 104959  |  VIC104959  |  VIC-104959

Class: Protein synthesis inhibitor

Agent Type: Synthetic; Small molecule; Direct acting;
Spectrum of activity: Gram-positive & Gram-negative
Mechanism of action: Protein synthesis inhibitor. Peptide deformylase inhibitor
Target Pathogen: Active against Staphylococcus aureus, Mycoplasma pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Moraxella catarrhalis, Haemophilus influenzae, and Chlamydophila pneumoniae
Institute where first reported: Vernalis, UK; Novartis, Switzerland; Pfizer, US
Year first mentioned: 2000
Highest development stage: Phase 1
Development status: Inactive
Reason dropped: Showed toxicity issues and high frequency to select resistant mutants; caused reversible cyanosis and low oxygen saturation attributable to methemoglobinemia
Chemical structure(s):
Click here for structure editor
Molecular weight: 396.41
Iso. SMILES: CCCC[C@H](CN(C=O)O)C(=O)N1CCC[C@H]1C(=O)N=C2C=CC(=CN2O)F
InChI Key: AYCMYBACERJYNY-HIFRSBDPSA-N
Can. SMILES: CCCC[C@H](CN(C=O)O)C(=O)N1CCC[C@H]1C(=O)N=C2C=CC(=CN2O)F
InChI: InChI=1S/C18H25FN4O5/c1-2-3-5-13(10-21(27)12-24)18(26)22-9-4-6-15(22)17(25)20-16-8-7-14(19)11-23(16)28/h7-8,11-13,15,27-28H,2-6,9-10H2,1H3/t13-,15+/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/9690139
Guide to Pharmacology: LBM-415
Citations:
  • https://doi.org/10.1128/aac.49.10.4128-4136.2005
  • https://doi.org/10.1128/aac.48.10.4033-4036.2004
  • https://doi.org/10.1016/S0924-8579(03)00114-6

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.